Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 3,594 shares at $15.00 ($54K) on 2024-12-31, disclosed to the SEC on 2025-01-03.
Scheduled sale ($54k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |